Invasive aspergillosis complicated in a patient with non-small cell lung cancer harboring RET fusion during treatment with RET-TKIs: a case report and literature review

Pralsetinib and selpercatinib have been approved as specific tyrosine kinase inhibitors (TKIs) for the treatment of patients with non-small cell lung cancer (NSCLC) harboring rearranged during transfection (RET) fusion and mutation. However, adverse events associated with pralsetinib and selpercatin...

Full description

Saved in:
Bibliographic Details
Main Authors: Kaidiriye Setiwalidi, Yimeng Li, Yuyan Ma, Zhanpeng Hao, Yujia Zhao, Yuxin Zhang, Xuan Liang, Tao Tian, Zhiping Ruan, Yu Yao, Xiao Fu
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-11-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1431908/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846163713972764672
author Kaidiriye Setiwalidi
Yimeng Li
Yuyan Ma
Zhanpeng Hao
Yujia Zhao
Yuxin Zhang
Xuan Liang
Tao Tian
Zhiping Ruan
Yu Yao
Xiao Fu
author_facet Kaidiriye Setiwalidi
Yimeng Li
Yuyan Ma
Zhanpeng Hao
Yujia Zhao
Yuxin Zhang
Xuan Liang
Tao Tian
Zhiping Ruan
Yu Yao
Xiao Fu
author_sort Kaidiriye Setiwalidi
collection DOAJ
description Pralsetinib and selpercatinib have been approved as specific tyrosine kinase inhibitors (TKIs) for the treatment of patients with non-small cell lung cancer (NSCLC) harboring rearranged during transfection (RET) fusion and mutation. However, adverse events associated with pralsetinib and selpercatinib are not fully understood, especially in the real world. In this case, invasive aspergillosis that appeared concurrent with RET-TKI targeted therapy is proposed to be an additional adverse drug reaction (ADR) that was not mentioned in previous reports. Here, we describe the process of clinical diagnosis and treatment of invasive aspergillosis and attempt to explore its possible pathogenesis in association with RET-TKI targeted therapy, with the aim of providing clinicians a more in-depth understanding of the ADR associated with RET-TKIs, as well as to prevent serious outcomes caused by reduction or discontinuation of antitumor therapy.
format Article
id doaj-art-bf72cd5c8d3d4d33930a7185f492a834
institution Kabale University
issn 2234-943X
language English
publishDate 2024-11-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Oncology
spelling doaj-art-bf72cd5c8d3d4d33930a7185f492a8342024-11-19T05:10:10ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2024-11-011410.3389/fonc.2024.14319081431908Invasive aspergillosis complicated in a patient with non-small cell lung cancer harboring RET fusion during treatment with RET-TKIs: a case report and literature reviewKaidiriye SetiwalidiYimeng LiYuyan MaZhanpeng HaoYujia ZhaoYuxin ZhangXuan LiangTao TianZhiping RuanYu YaoXiao FuPralsetinib and selpercatinib have been approved as specific tyrosine kinase inhibitors (TKIs) for the treatment of patients with non-small cell lung cancer (NSCLC) harboring rearranged during transfection (RET) fusion and mutation. However, adverse events associated with pralsetinib and selpercatinib are not fully understood, especially in the real world. In this case, invasive aspergillosis that appeared concurrent with RET-TKI targeted therapy is proposed to be an additional adverse drug reaction (ADR) that was not mentioned in previous reports. Here, we describe the process of clinical diagnosis and treatment of invasive aspergillosis and attempt to explore its possible pathogenesis in association with RET-TKI targeted therapy, with the aim of providing clinicians a more in-depth understanding of the ADR associated with RET-TKIs, as well as to prevent serious outcomes caused by reduction or discontinuation of antitumor therapy.https://www.frontiersin.org/articles/10.3389/fonc.2024.1431908/fullNSCLCRETpralsetinibselpercatinibinvasive aspergillosis
spellingShingle Kaidiriye Setiwalidi
Yimeng Li
Yuyan Ma
Zhanpeng Hao
Yujia Zhao
Yuxin Zhang
Xuan Liang
Tao Tian
Zhiping Ruan
Yu Yao
Xiao Fu
Invasive aspergillosis complicated in a patient with non-small cell lung cancer harboring RET fusion during treatment with RET-TKIs: a case report and literature review
Frontiers in Oncology
NSCLC
RET
pralsetinib
selpercatinib
invasive aspergillosis
title Invasive aspergillosis complicated in a patient with non-small cell lung cancer harboring RET fusion during treatment with RET-TKIs: a case report and literature review
title_full Invasive aspergillosis complicated in a patient with non-small cell lung cancer harboring RET fusion during treatment with RET-TKIs: a case report and literature review
title_fullStr Invasive aspergillosis complicated in a patient with non-small cell lung cancer harboring RET fusion during treatment with RET-TKIs: a case report and literature review
title_full_unstemmed Invasive aspergillosis complicated in a patient with non-small cell lung cancer harboring RET fusion during treatment with RET-TKIs: a case report and literature review
title_short Invasive aspergillosis complicated in a patient with non-small cell lung cancer harboring RET fusion during treatment with RET-TKIs: a case report and literature review
title_sort invasive aspergillosis complicated in a patient with non small cell lung cancer harboring ret fusion during treatment with ret tkis a case report and literature review
topic NSCLC
RET
pralsetinib
selpercatinib
invasive aspergillosis
url https://www.frontiersin.org/articles/10.3389/fonc.2024.1431908/full
work_keys_str_mv AT kaidiriyesetiwalidi invasiveaspergillosiscomplicatedinapatientwithnonsmallcelllungcancerharboringretfusionduringtreatmentwithrettkisacasereportandliteraturereview
AT yimengli invasiveaspergillosiscomplicatedinapatientwithnonsmallcelllungcancerharboringretfusionduringtreatmentwithrettkisacasereportandliteraturereview
AT yuyanma invasiveaspergillosiscomplicatedinapatientwithnonsmallcelllungcancerharboringretfusionduringtreatmentwithrettkisacasereportandliteraturereview
AT zhanpenghao invasiveaspergillosiscomplicatedinapatientwithnonsmallcelllungcancerharboringretfusionduringtreatmentwithrettkisacasereportandliteraturereview
AT yujiazhao invasiveaspergillosiscomplicatedinapatientwithnonsmallcelllungcancerharboringretfusionduringtreatmentwithrettkisacasereportandliteraturereview
AT yuxinzhang invasiveaspergillosiscomplicatedinapatientwithnonsmallcelllungcancerharboringretfusionduringtreatmentwithrettkisacasereportandliteraturereview
AT xuanliang invasiveaspergillosiscomplicatedinapatientwithnonsmallcelllungcancerharboringretfusionduringtreatmentwithrettkisacasereportandliteraturereview
AT taotian invasiveaspergillosiscomplicatedinapatientwithnonsmallcelllungcancerharboringretfusionduringtreatmentwithrettkisacasereportandliteraturereview
AT zhipingruan invasiveaspergillosiscomplicatedinapatientwithnonsmallcelllungcancerharboringretfusionduringtreatmentwithrettkisacasereportandliteraturereview
AT yuyao invasiveaspergillosiscomplicatedinapatientwithnonsmallcelllungcancerharboringretfusionduringtreatmentwithrettkisacasereportandliteraturereview
AT xiaofu invasiveaspergillosiscomplicatedinapatientwithnonsmallcelllungcancerharboringretfusionduringtreatmentwithrettkisacasereportandliteraturereview